A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.

BRAFV600E hyperactivates ERK and signals as a RAF inhibitor-sensitive monomer. Although RAF inhibitors can produce impressive clinical responses in patients with mutant BRAF tumors, the mechanisms of resistance to these drugs are incompletely characterized. Here, we report a complete response followed by clinical progression in a patient with a BRAFV600E-mutant brain tumor treated with dabrafenib. Whole-exome sequencing revealed a secondary BRAFL514V mutation at progression that was not present in the pretreatment tumor. Expressing BRAFV600E/L514V induces ERK signaling, promotes RAF dimer formation, and is sufficient to confer resistance to dabrafenib. Newer RAF dimer inhibitors and an ERK inhibitor are effective against BRAFL514V-mediated resistance. Collectively, our results validate a novel biochemical mechanism of RAF inhibitor resistance mediated by a secondary mutation, emphasizing that, like driver mutations in cancer, the spectrum of mutations that drive resistance to targeted therapy are heterogeneous and perhaps emerge with a lineage-specific prevalence.Significance: In contrast to receptor tyrosine kinases, in which secondary mutations are often responsible for acquired resistance, second-site mutations in BRAF have not been validated in clinically acquired resistance to RAF inhibitors. We demonstrate a secondary mutation in BRAF (V600E/L514V) following progression on dabrafenib and confirm functionally that this mutation is responsible for resistance. Cancer Discov; 8(9); 1130-41. ©2018 AACR.See related commentary by Romano and Kwong, p. 1064This article is highlighted in the In This Issue feature, p. 1047.

[1]  Lu Wang,et al.  Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. , 2017, Cancer research.

[2]  B. Taylor,et al.  Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS , 2017, Nature.

[3]  K. Ligon,et al.  Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. Hahn,et al.  A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas , 2017, Neuro-oncology.

[5]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[6]  Gennady M Verkhivker,et al.  Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways , 2016, PloS one.

[7]  M. Herlyn,et al.  An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. , 2016, Cancer cell.

[8]  C. Der,et al.  RAS isoforms and mutations in cancer at a glance , 2016, Journal of Cell Science.

[9]  Shih-Hsun Chen,et al.  Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. , 2016, Cancer discovery.

[10]  C. Berking,et al.  Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. , 2015, European journal of cancer.

[11]  James Tsai,et al.  RAF inhibitors that evade paradoxical MAPK pathway activation , 2015, Nature.

[12]  O. Abdel-Wahab,et al.  BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. , 2015, Cancer cell.

[13]  Xiwen Ma,et al.  Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. , 2015, Cancer cell.

[14]  J. Blay,et al.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.

[15]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[16]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[17]  E. Cuppen,et al.  Detailed imaging and genetic analysis reveal a secondary BRAFL505H resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib , 2015, Pigment cell & melanoma research.

[18]  Nikhil Wagle,et al.  Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. , 2015, Cancer discovery.

[19]  D. Merico,et al.  BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Frank McCormick,et al.  Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond , 2014, Nature Reviews Cancer.

[21]  Dirk Schadendorf,et al.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.

[22]  G. Pupo,et al.  BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact , 2014, Clinical Cancer Research.

[23]  Michael R. Green,et al.  Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain , 2014, Pigment cell & melanoma research.

[24]  R. Bjornson,et al.  Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors , 2013, Pigment cell & melanoma research.

[25]  Wei Xu,et al.  Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. , 2013, Cell reports.

[26]  Tomoyasu Ishikawa,et al.  Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. , 2013, Journal of medicinal chemistry.

[27]  Shuxia Zhao,et al.  Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.

[28]  A. Resnick,et al.  Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas , 2013, Proceedings of the National Academy of Sciences.

[29]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[30]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[31]  Qiongqing Wang,et al.  Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. , 2012, Cancer research.

[32]  S. Nelson,et al.  Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.

[33]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[34]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[35]  S. Pileri,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[36]  Jonathan Chernoff,et al.  Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. , 2011 .

[37]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[38]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[39]  W. Hahn,et al.  Recurrent BRAF mutations in Langerhans cell histiocytosis. , 2010, Blood.

[40]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[41]  B. Taylor,et al.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.

[42]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[43]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[44]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[45]  Hanlee P. Ji,et al.  Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. , 2010, Cancer research.

[46]  William Pao,et al.  Genetic predictors of MEK dependence in non-small cell lung cancer. , 2008, Cancer research.

[47]  S. Hirota,et al.  Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib‐resistant gastrointestinal stromal tumor , 2008, Cancer science.

[48]  William Pao,et al.  Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors , 2006, Clinical Cancer Research.

[49]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[50]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[51]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[52]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[53]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[54]  Caroline Robert,et al.  Safety and efficacy of vemurafenib in BRAF V 600 E and BRAF V 600 K mutation-positive melanoma ( BRIM-3 ) : extended follow-up of a phase 3 , randomised , open-label study , 2015 .

[55]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[56]  A. McCullough.  RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors , 2013 .